Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 2, 2026Open Access

A Comprehensive Review: Platinum Based Chemotherapy in Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Key result

Platinum-based chemotherapy combined with newer cytotoxic drugs improves lung cancer survival despite significant toxicities.

Why the study?

Despite newer therapies, platinum-based chemotherapy remains fundamental in lung cancer management, but its use is constrained by toxicities and resistance.

Design

Review

Authors

VPV. V. V. Satya Durga1*, K. Gayathri2, J. Jahnavi3, M. Harshitha4, Dr. B. Bhavani5, Dr. K. Padmalatha6

Discussion

Loading...

Member takes

Implication

Supports continued platinum use in lung cancer; leaves open optimal integration with targeted therapies and resistance mitigation.

Key Points

  • To critically examine the pharmacological mechanisms, clinical efficacy, adverse toxicity profiles, resistance pathways, and emerging therapeutic directions of platinum-based chemotherapy in lung cancer.
  • Narrative review synthesizing pharmacology, clinical trial outcomes, and molecular mechanisms of platinum compounds across non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
  • Analysis of systemic therapeutic combinations involving cisplatin and carboplatin alongside targeted therapies, radiotherapy, and immunotherapy in neoadjuvant, adjuvant, and palliative settings.
  • Platinum compounds exert antitumor activity primarily through the formation of intra-strand and inter-strand DNA cross-links that disrupt DNA replication and activate apoptotic pathways.
  • Combining platinum agents with newer cytotoxic drugs yields superior survival outcomes and symptomatic relief compared with non-platinum regimens in NSCLC (80–85% of cases) and SCLC (15–20% of cases), where five-year survival remains below 25%.
  • Therapeutic utility remains constrained by dose-dependent toxicities—including renal impairment, neurotoxicity, ototoxicity, and bone marrow suppression—alongside intrinsic or acquired resistance via enhanced DNA repair and altered drug transport.

Structured PICO

P
Population
Patients with non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC)
I
Intervention
Platinum-based chemotherapy (cisplatin and carboplatin)

Platinum-based chemotherapy remains a fundamental component of lung cancer management across multiple stages of disease, despite the advent of targeted therapies and immunotherapy.

Limitations

  • Dose-dependent toxicities including renal impairment, neurotoxicity, ototoxicity, and bone marrow suppression
  • Intrinsic and acquired resistance to platinum chemotherapy

Cite This Study

V. V. V. Satya Durga1*, K. Gayathri2, J. Jahnavi3, M. Harshitha4, Dr. B. Bhavani5, Dr. K. Padmalatha6 (2026) conducted a review in Lung cancer (NSCLC and SCLC). Platinum-based chemotherapy (Cisplatin and Carboplatin) was evaluated. Platinum-based chemotherapy, particularly cisplatin and carboplatin, remains a fundamental component of lung cancer management across multiple stages of disease.

synapsesocial.com/papers/6980ff26c1c9540dea811dc9https://doi.org/10.5281/zenodo.18427344
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Research Progress of Platinum-Based Complexes in Lung Cancer Treatment: Mechanisms, Applications, and Challenges2025 · 12 citations
  2. 2A COMPREHENSIVE REVIEW OF CISPLATIN: FROM CHEMICAL EVOLUTION TO ADVANCED THERAPEUTIC STRATEGIES2026
  3. 3A COMPREHENSIVE REVIEW OF CISPLATIN: FROM CHEMICAL EVOLUTION TO ADVANCED THERAPEUTIC STRATEGIES2026
  4. 4Platinum‐Based Chemotherapeutics in the Modern Era: From Classical DNA ‐Targeting Mechanisms to Next‐Generation Innovations in Cancer Therapy2025 · 9 citations
  5. 5Cisplatin and platinum drugs at the molecular level (Review)2003 · 731 citations